Account
06.03.2025
How to navigate early payer scientific advice: a B...

Charlie Hewitt from Remap Consulting initiated today’s session by providing a description of the c...

Read more
28.02.2025
Unlocking Access: The Role of Patient Engagement i...

AUTHORS: ​Joyce Atim, Rahul Vadehra​ Rare diseases have a significant impact on people worldwide...

Read more
Articles
25.02.2025
How are countries implementing the EU HTA Regulati...

EU HTA Regulation goes live: A new era for HTA begins  The much-awaited implementation of the r...

Read more
08.01.2025
Pricing and Market Access trends: 2025

Our review of the 2024 pricing and market access revealed key challenges facing the pharmaceutical i...

Read more
Webinar
07.11.2024
Breaking new ground: key learnings from one of the...

Remap Consulting presents ground-breaking insights and practical learnings from one of the pioneerin...

Read more
Publications
15.10.2024
WODC Europe 2024: Comparing And Contrasting Early ...

AUTHORS: Amy Boyers, Solen Monteil, Mariam Bibi OBJECTIVES  Early Access Programmes (EAPs) prov...

Read more
04.10.2024
EU releases draft implementing act on Joint Scient...

The European Commission's 4th implementing act outlines how health tech developers can obtain early ...

Read more
Articles
17.09.2024
Can Real-World Evidence overcome uncertainty in Ra...

We examine how real-world evidence strategies help address uncertainties in rare disease treatments ...

Read more
Articles
10.09.2024
Strategic approaches to achieving HTA approval for...

Achieving HTA approval for orphan drugs requires strategic planning, early engagement, strong eviden...

Read more
News
03.09.2024
World Orphan Drug Congress Europe 2024

We're thrilled to announce our participation at World Orphan Drug Congress Europe 2024 in Barcelona ...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.